C12N 2310/53
Partially self-complementary or closed
Official title: partially self-complementary or closed
C12N2310/53 (Partially self-complementary or closed) appears on 2,145 US grants and 4,368 published applications in this corpus.
Search patents in C12N- Granted patents
- 2,145
- Published applications
- 4,368
- Assignees
- 1,406
- Inventors
- 6,825
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 6 | 0 |
| 1996 | 8 | 0 |
| 1997 | 27 | 0 |
| 1998 | 43 | 0 |
| 1999 | 17 | 0 |
| 2000 | 16 | 0 |
| 2001 | 17 | 1 |
| 2002 | 13 | 19 |
| 2003 | 9 | 64 |
| 2004 | 5 | 106 |
| 2005 | 9 | 156 |
| 2006 | 15 | 109 |
| 2007 | 12 | 93 |
| 2008 | 24 | 89 |
| 2009 | 37 | 141 |
| 2010 | 64 | 130 |
| 2011 | 56 | 138 |
| 2012 | 84 | 102 |
| 2013 | 78 | 116 |
| 2014 | 102 | 155 |
| 2015 | 112 | 216 |
| 2016 | 96 | 228 |
| 2017 | 129 | 217 |
| 2018 | 137 | 220 |
| 2019 | 152 | 226 |
| 2020 | 145 | 237 |
| 2021 | 123 | 233 |
| 2022 | 125 | 264 |
| 2023 | 135 | 297 |
| 2024 | 114 | 283 |
| 2025 | 111 | 310 |
| 2026 | 123 | 218 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Gene therapy for neurodegenerative disorders using polynucleotide silencing and replacement6 Oct 2026US 12,753,411 B2The Brigham and Women S Hospital, Inc.
- Methods of activating cells via PTP 1B inhibition29 Sep 2026US 12,746,285 B2Monash University
- Compositions and methods for reprogramming age-restricted non-neuronal cells29 Sep 2026US 12,747,438 B2The Regents of the University of California
- Use of FcgammaRIII inhibitor in preparation of medicament for treating pulmonary fibrosis15 Sep 2026US 12,735,489 B2Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences
- Enzymes with RUVC domains15 Sep 2026US 12,735,688 B2Metagenomi Therapeutics, Inc.
- Methods and compositions for microbial delivery of double stranded rna8 Oct 2026US 2026/0305618 A1Rnaissance AG LLC
- Sugar Modified Oligonucleotides and Uses Thereof8 Oct 2026US 2026/0308587 A1Ionis Pharmaceuticals, Inc.
- Nucleic acids encoding crispr-associated proteins and uses thereof8 Oct 2026US 2026/0308602 A1CureVac AG
- Compositions and methods for recombinant aav production8 Oct 2026US 2026/0308620 A1REGENXBIO Inc.
- Methods for treating gastrointestinal inflammatory diseases using alpha-ketoglutarate (akg) modulators1 Oct 2026US 2026/0294856 A1
Most cited
By later US patents
- Genetic inhibition by double-stranded RNA1,185US 6,506,559 B1Carnegie Institute of Washington · 2003
- Methods for identifying nucleic acid ligands856US 5,270,163 AUniversity Research Corporation · 1993
- Nucleic acid ligands561US 5,475,096 AUniversity Research Corporation · 1995
- CRISPR-Cas component systems, methods and compositions for sequence manipulation560US 8,795,965 B2Massachusetts Institute of Technology · 2014
- CRISPR-Cas component systems, methods and compositions for sequence manipulation529US 8,871,445 B2Massachusetts Institute of Technology · 2014